Having grown up in rural Australia and trained in medicine in Australia, the UK, Ireland and USA, Alicia is an endocrinologist with expertise in diabetes and vascular (heart and blood vessels) medicine. With over 3-decades of specialist clinical experience and of research, Alicia is interested in the prediction and prevention of the complications of Type 1 and Type 2 diabetes, cardiovascular disease and in the use of technology in healthcare. She is also a strong advocate for equitable access for healthcare.

Alicia’s team has an extensive national and international network of collaborators and undertakes clinical (people-based) research with and for people with diabetes, including clinical trials and related laboratory-based studies. She has a biomarker laboratory with a wide range of clinical, biochemical and molecular tools that can be applied to their own studies and are available for other researchers to use. She has over 450 publications, cited over 14,295 times, and an H-index of 62. Alicia is Chief Editor of three books: Lipoproteins in Diabetes Mellitus (Humana Press, 2014 and 2023 editions) and (in preparation) Care of mature aged adults with type 1 diabetes. She also led the Diabetes and Disasters Care Manual for the International Diabetes Federation, Western Pacific Region (2nd edition, 2022).

Her team includes clinical and science trainees from undergraduate to postgraduate level.  She has trained over 100 biomedical researchers, including 20 higher research (e.g., PhD) candidates.

Alicia serves on grant review panels and advisory boards, including for Diabetes Australia, the International Diabetes Federation and industry, conference conduct, editorial roles and guideline developing groups. She is available as a speaker for community groups and is actively engaged with international humanitarian diabetes aid organisations such as Insulin for Life.

She has lead roles in clinical trials: REMOVAL trial of metformin in Type 1 diabetes (T1D), fenofibrate trials (FIELD (Type 2 diabetes, FAME-1 Eye (T1D) trial), insulin pump and sensor trials, T4DM (testosterone for pre-diabetes) and colchicine for cardiovascular disease. She is a CI on a NHMRC Centre For Research Excellence for cardiovascular disease and a Program Grant re trial design and conduct.  Alicia also has lead roles in new models of Indigenous Australian eye care and in major international diabetes cohort studies: DCCT/EDIC, Hong Kong Diabetes Registry and Finn Diane.

She is an Co-Director of the Australian CardioVascular Alliance (ACVA) Precision Medicine Flagship, and an active member of the Diabetes Technology Research Group (DTRG) and Australian Centre for Acceleration Diabetes Innovations (ACADI).